Silverback Therapeutics (NASDAQ:SBTX – Get Free Report) and Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Silverback Therapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
| Phathom Pharmaceuticals | -1,292.14% | N/A | -79.57% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Silverback Therapeutics and Phathom Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silverback Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Phathom Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
Risk & Volatility
Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.
Earnings and Valuation
This table compares Silverback Therapeutics and Phathom Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -5.99 |
| Phathom Pharmaceuticals | $81.86 million | 7.53 | -$201.59 million | ($5.24) | -1.69 |
Silverback Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Phathom Pharmaceuticals beats Silverback Therapeutics on 8 of the 14 factors compared between the two stocks.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
